Cipla Limited has informed the stock exchanges that the United States Food and Drug Administration (USFDA) conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility of its wholly owned subsidiary, InvaGen Pharmaceuticals Inc., located in Central Islip, Long Island, New York, USA.

The inspection was carried out from July 13 to July 17, 2026 (EDT) as part of the USFDA's routine regulatory oversight of pharmaceutical manufacturing facilities.

A new survey has uncovered significant knowledge gaps among families with a history of type 1 diabetes (T1D), highlighting misconceptions that may delay early screening and diagnosis despite their increased risk of developing the disease.

The survey, titled "The Family Factor: A T1D Risk Awareness Survey," was conducted by global diabetes nonprofit Beyond Type 1 and commissioned by Sanofi. It focused on adults and caregivers with a first-degree family member living with type 1 diabetes.

An international research team led by the Medical University of Vienna has investigated a new peptide derived from cone snail venom which significantly reduced inflammation-induced pain in an animal model. Crucially, its effect takes hold immediately after subcutaneous injection, whereas previously known cone snail peptides must be administered directly into the cerebrospinal fluid.

Modern research on secondary metabolites from microbes, plants, and marine organisms has revealed a remarkable diversity of chemical structures and bioactivities with broad applications in biotechnology, agriculture, and medicine. Most natural products are composed of primary biogenic elements such as carbon, hydrogen, nitrogen, and oxygen.  

Applications are invited from eligible candidates for the position of Project Technical Support - III in an ICMR-funded Research Project entitled Development of In Vitro Diagnostic (IVD) Kits against drug-resistant Salmonella Infections’

JRF Position

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.

Alembic Pharmaceuticals Limited (Alembic) today announced that its Partner NATCO Pharma Limited (NATCO) has received tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Olaparib Tablets, 100 mg and 150 mg. 

In a landmark development for dengue prevention, the Drug Controller General of India (DCGI) has granted market authorization to Takeda Biopharmaceuticals India's QDENGA (Dengue Tetravalent Vaccine [Live, Attenuated]), making it the first dengue vaccine approved in India. The vaccine is approved for the prevention of dengue in individuals 4 to 60 years of age and can be administered regardless of prior dengue infection, eliminating the need for pre-vaccination screening.